Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Text Size

Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00445484
First received: March 7, 2007
Last updated: August 5, 2015
Last verified: August 2015
History of Changes
  Purpose

RATIONALE: Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Vaccines may help the body build an effective immune response to kill cancer cells. Giving lenalidomide together with vaccine therapy may make a stronger immune response and kill more cancer cells.

PURPOSE: This phase II trial is studying how well giving lenalidomide together with vaccine therapy works in treating patients with relapsed or refractory multiple myeloma.


Condition Intervention Phase
Multiple Myeloma and Plasma Cell Neoplasm
 Biological: pneumococcal polyvalent vaccine
Drug: lenalidomide
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Revlimid to Augment Efficacy of Prevnar Vaccines in Patients With Relapsed or Refractory Myeloma

Resource links provided by NLM:

MedlinePlus related topics: Multiple Myeloma
U.S. FDA Resources

Further study details as provided by Sidney Kimmel Comprehensive Cancer Center:

Primary Outcome Measures:
  • 6B Antibody Response to Prevnar Vaccine in Peripheral Blood [ Time Frame: basline and 8 weeks after second vaccination ]
    Serum IgG levels against the PVC serotype were measured by ELISA

  • 14F Antibody Response to Prevnar Vaccine in Peripheral Blood [ Time Frame: basline and 8 weeks after second vaccination ]
    Serum IgG levels against the PVC serotype were measured by ELISA

  • 19F Antibody Response to Prevnar Vaccine in Peripheral Blood [ Time Frame: basline and 8 weeks after second vaccination ]
    Serum IgG levels against the PVC serotype were measured by ELISA

  • 23F Antibody Response to Prevnar Vaccine in Peripheral Blood [ Time Frame: basline and 8 weeks after second vaccination ]
    Serum IgG levels against the PVC serotype were measured by ELISA
Enrollment: 22
Study Start Date: January 2007
Study Completion Date: September 2010
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group 1
Patients receive oral lenalidomide on days 1-21. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity. Patients receive pneumococcal polyvalent vaccine intramuscularly (IM) 14 days prior to beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
 Biological: pneumococcal polyvalent vaccine
Given intramuscularly
Drug: lenalidomide
Given orally
Experimental: Group 2
Patients receive lenalidomide as in group 1. Patients receive pneumococcal polyvalent vaccine IM approximately 45 days after beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
 Biological: pneumococcal polyvalent vaccine
Given intramuscularly
Drug: lenalidomide
Given orally

Detailed Description:

OBJECTIVES:

Primary

  • Determine whether lenalidomide can augment the efficacy of pneumococcal polyvalent vaccine as it correlates with lenalidomide-induced antitumor efficacy in patients with relapsed or refractory multiple myeloma.

Secondary

  • Determine the antibody responses to pneumococcal serotypes in patients treated with this regimen.
  • Determine T-cell responses to the carrier protein CRM 197 in patients treated with this regimen.
  • Determine the ability of lenalidomide to augment in vivo immune responsiveness as measured by cutaneous delayed-type hypersensitivity (DTH) reactions to Candida and tetanus in these patients.
  • Determine the ability of lenalidomide to prime and/or boost systemic vaccine responses in both peripheral blood lymphocytes and marrow lymphocytes in these patients.

OUTLINE: Patients are assigned to 1 of 2 treatment groups.

  • Group 1: Patients receive oral lenalidomide on days 1-21. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity. Patients receive pneumococcal polyvalent vaccine intramuscularly (IM) 14 days prior to beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
  • Group 2: Patients receive lenalidomide as in group 1. Patients receive pneumococcal polyvalent vaccine IM approximately 45 days after beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).

After completion of study treatment, patients are followed at 30 days.

PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.

  Eligibility
Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Diagnosis of multiple myeloma (MM) meeting all of the following criteria:

    • Relapsed or refractory disease
    • Previously received ≥ 2 courses of antimyeloma treatment
  • Measurable levels of myeloma paraprotein in serum (> 0.5 g/dL) or urine (> 0.2 g/24-hour urine collection) OR serum-free light-chain disease

PATIENT CHARACTERISTICS:

  • ECOG performance status 0-2
  • Absolute neutrophil count ≥ 1,000/mm^3
  • Platelet count ≥ 75,000/mm^3
  • Creatinine ≤ 2.5 mg/dL
  • Bilirubin ≤ 2.0 mg/dL
  • AST and ALT ≤ 3 times upper limit of normal
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use 2 methods of highly effective contraception ≥ 4 weeks before, during, and for 4 weeks after completion of study therapy
  • No other malignancy within the past 5 years except treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast
  • No serious medical condition, laboratory abnormality, or psychiatric illness that would preclude study treatment or put patient at unacceptable risk

  • No known hypersensitivity to thalidomide or lenalidomide

    • No development of erythema nodosum in the presence of a reaction characterized by a desquamating rash while taking thalidomide or similar drugs
  • No known hypersensitivity to any component of the pneumococcal polyvalent vaccine, including diphtheria toxin or CRM 197
  • No known HIV positivity
  • No infectious hepatitis type A, B, or C

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • No more than 3 prior treatment regimens for MM
  • More than 6 months since prior lenalidomide
  • More than 28 days since prior experimental drug or therapy
  • More than 1 month since prior systemic antimyeloma therapy
  • More than 1 month since prior and no concurrent systemic corticosteroids
  • No other concurrent anticancer agents or treatments or investigational agents
  • No concurrent thalidomide
  • No concurrent radiotherapy
  • No other concurrent immune therapy or immunomodulatory agents
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00445484

Locations
United States, Maryland
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States, 21231-2410
Sponsors and Collaborators
Sidney Kimmel Comprehensive Cancer Center
National Cancer Institute (NCI)
Investigators
Study Chair: Ivan Borrello, MD Sidney Kimmel Comprehensive Cancer Center
  More Information

Publications:

Responsible Party: Sidney Kimmel Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT00445484     History of Changes
Other Study ID Numbers: J06102 CDR0000532944
P30CA006973 ( US NIH Grant/Contract Award Number )
JHOC-J06102
JHOC-NA_00006008
CELGENE-CC-5013
Study First Received: March 7, 2007
Results First Received: June 26, 2015
Last Updated: August 5, 2015

Keywords provided by Sidney Kimmel Comprehensive Cancer Center:
stage II multiple myeloma
stage III multiple myeloma
refractory multiple myeloma

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Plasmacytoma
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
 Vaccines
Lenalidomide
Thalidomide
Heptavalent Pneumococcal Conjugate Vaccine
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents
Immunosuppressive Agents
Leprostatic Agents
Anti-Bacterial Agents
Anti-Infective Agents

ClinicalTrials.gov processed this record on May 25, 2017